Videos

Dr John Mascarenhas explains the differences between myelofibrosis phenotypes and why it affects treatment regimen choices.

Robert J. Soiffer, MD, discusses how the role of transplantation is evolving with the availability of chimeric antigen receptor T-cell agents.

John Mascarenhas, MD, presents the case of a 76-year-old woman with myelofibrosis and provides his initial impressions.

Samuel J. Klempner, MD, discusses the mechanism of action of the investigational agent DKN-01 in patients with gastroesophageal adenocarcinoma.

Srdan Verstovsek, MD, PhD, wraps up by discussing remaining unmet needs and hopes for future treatment options for patients with MF.

A commentary on considerations for long-term follow-up and management of myelofibrosis.

Srdan Verstovsek, MD, PhD, discusses the risk of transformation to acute myeloid leukemia (AML) and the potential use of bone marrow transplant in patients with MF.

A discussion of the benefits of clinical trial enrollment for MF.

Srdan Verstovsek, MD, PhD, reviews how treatment with JAK inhibitors improves symptoms, quality of life, and patient outcomes in primary MF.

Srdan Verstovsek, MD, PhD, comments on safety data from the ruxolitinib clinical trials in patients with MF.

A comprehensive review of key efficacy data from clinical trials on ruxolitinib, including COMFORT-I and COMFORT-II.

Srdan Verstovsek, MD, PhD, expands upon frontline treatment options for primary MF, including Janus kinase (JAK) inhibitors.

A focused discussion on the clinical factors that impact patient prognosis, risk assessment, and disease progression.

Srdan Verstovsek, MD, PhD, reviews the use of symptom scoring systems and prognostic models for MF risk stratification and treatment selection.

An overview of clinical criteria and tools that clinicians use for diagnosis of MF.

Srdan Verstovsek, MD, PhD, comments on the patient profile and discusses the typical presentation of patients with myelofibrosis (MF).

Dr Naveen Pemmaraju discusses exciting potential treatment options in myelofibrosis and some unmet needs and ongoing challenges in the treatment landscape.

Naveen Pemmaraju, MD, talks about the potential implications of the phase II REFINE trial on the myelofibrosis treatment paradigm.

A review of the study design and key efficacy and safety outcomes of the REFINE trial studying ruxolitinib plus navitoclax treatment in myelofibrosis.

Naveen Pemmaraju, MD, describes the currently available treatment options for patients with myelofibrosis.

Dr Naveen Pemmaraju explains the relationship of the JAK/STAT pathway to myelofibrosis and the molecular mutations he looks for with biomarker testing.

Naveen Pemmaraju, MD, provides an overview of myelofibrosis, including a comparison of primary and secondary myelofibrosis and the risk stratification.

Lyudmila A. Bazhenova, MD, discusses targeted therapies for patients with MET-mutated non–small cell lung cancer.

John Allan, MD, speaks to the exciting future of treatments for chronic lymphocytic leukemia.

Dr John Allan discusses the adverse events he monitors for with select treatments for chronic lymphocytic leukemia, and when he decides to move to second-line therapy.

An expert in hematologic malignancies describes how he would monitor a patient on frontline treatment with newly diagnosed chronic lymphocytic leukemia.

John Allan, MD, explains how fitness level and comorbidities affect his treatment selections for chronic lymphocytic leukemia and whether he prefers fixed-duration or continuous-strategy approaches.

Dr John Allan gives an overview of the frontline treatment options available for chronic lymphocytic leukemia with reference to clinical trial data.

A leukemia expert discusses ongoing challenges in chronic lymphocytic leukemia treatment, and how to discuss risk stratification with a patient.

John Allan, MD, presents the case of a 70-year-old woman with newly diagnosed chronic lymphocytic leukemia.